Dietrich Stephan

NeuBase Therapeutics Announces Receipt of Notice from Nasdaq

Retrieved on: 
Friday, April 5, 2024
Dietrich Stephan, Rule, Notice, Form, Risk, Annual report, Therapy, Calendar, Cryptocurrency

This Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market.

Key Points: 
  • This Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market.
  • Under Nasdaq rules, the Company has 60 calendar days from receipt of the Notice, or until June 3, 2024, to submit a plan to regain compliance with the Rule.
  • These forward-looking statements include, without limitation, statements relating to our continued listing on Nasdaq and any exception that may be granted by Nasdaq.
  • Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements.

NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder

Retrieved on: 
Friday, September 8, 2023
Uncertainty, Biotechnology, Risk, Schedule, Dietrich Stephan, Acquisition, Therapy

PITTSBURGH, Sept. 08, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation (“Symetryx”) and their subsequent press release issued on September 6, 2023.

Key Points: 
  • PITTSBURGH, Sept. 08, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation (“Symetryx”) and their subsequent press release issued on September 6, 2023.
  • “The NeuBase Board of Directors (“Board”) appreciates input from its shareholders.
  • The Board remains committed to completing its comprehensive exploration of strategic alternatives focused on maximizing shareholder value.
  • The Board does not believe that shareholder value will be enhanced by issuing the special $1 per share dividend Symetryx requested in their press release.

NeuBase Therapeutics to Explore Strategic Alternatives

Retrieved on: 
Thursday, August 3, 2023
Uncertainty, Biotechnology, Gene editing, Disclosure, Risk, Dietrich Stephan, Acquisition, Immune system, Stealth, Therapy

The Board has made the determination to halt further development of the Company’s programs and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.

Key Points: 
  • The Board has made the determination to halt further development of the Company’s programs and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.
  • As part of this evaluation process, the Board will explore potential strategic alternatives for the Company that may include, but are not limited to, an acquisition, merger, business combination, or other transaction.
  • There can be no assurance that this evaluation process will result in NeuBase pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms, if at all.
  • These forward-looking statements include, without limitation, statements relating to our conducting a comprehensive evaluation of strategic alternatives focused on maximizing shareholder value; evaluating potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, or other transaction and the completion of such a review process.

NeuBase Announces Closing of $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Friday, June 30, 2023
Exercise, Gene editing, Park Avenue, Regulation D, Securities and Exchange Commission (Philippines), Sale, Dietrich Stephan, 3rd Floor, Immune system, Form, Security (finance), Stealth, Therapy

The registered direct offering and the private placement were priced at-the-market under Nasdaq rules.

Key Points: 
  • The registered direct offering and the private placement were priced at-the-market under Nasdaq rules.
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offerings.
  • The gross proceeds to the Company from the concurrent offerings are approximately $5 million, before deducting the placement agent’s fees and other offering expenses payable by NeuBase.
  • The offering of the securities issued in the registered direct offering was made only by means of a prospectus supplement that forms a part of the registration statement.

NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to Redosing

Retrieved on: 
Thursday, June 29, 2023
MSD, DNA, MC3, APS, Serum, Gene editing, Mutation, IL-6, IL10, PNA, Dietrich Stephan, Development, IL-8, Blood, Immune system, Nucleic acid, Frameshift mutation, NHP, Cytokine, Research, LNP, Therapy, Death, Oligonucleotide, Pharmacology, Genome, Vaccine, Palladium, Stealth

For these reasons, we are on a mission to develop the next generation of editors that are non-immunogenic,” continued Dr. Stephan.

Key Points: 
  • For these reasons, we are on a mission to develop the next generation of editors that are non-immunogenic,” continued Dr. Stephan.
  • The conclusion from these data is that Stealth Editors do not elicit innate nor acquired immune responses in the encapsulated format in which they would be administered systemically.
  • The Company believes this is likely to be an important differentiator of its technology when transitioned to in vivo gene editing.
  • Ex vivo Editing with Stealth Editors - The Company investigated the capabilities of a new editing system to effectively edit human cells ex vivo.

NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Wednesday, June 28, 2023
Exercise, Gene editing, Park Avenue, Regulation D, Sale, Dietrich Stephan, 3rd Floor, Immune system, Form, Security (finance), Stealth, Therapy

In a concurrent private placement, NeuBase has also agreed to issue and sell an aggregate of 1,366,829 of its shares of common stock (or common stock equivalents), at the same purchase price of $2.57 per share (or common stock equivalent) and associated unregistered warrants as in the registered direct offering.

Key Points: 
  • In a concurrent private placement, NeuBase has also agreed to issue and sell an aggregate of 1,366,829 of its shares of common stock (or common stock equivalents), at the same purchase price of $2.57 per share (or common stock equivalent) and associated unregistered warrants as in the registered direct offering.
  • The registered direct offering and the private placement were priced at-the-market under Nasdaq rules.
  • The gross proceeds to the Company from the concurrent offerings are expected to be approximately $5 million, before deducting the placement agent’s fees and other offering expenses payable by NeuBase.
  • The offering of the securities to be issued in the registered direct offering is being made only by means of a prospectus supplement that forms a part of the registration statement.

NeuBase Announces 1-for-20 Reverse Stock Split

Retrieved on: 
Wednesday, June 14, 2023
Transfer, Exercise, Gene editing, Leesburg Transfer Company, Dietrich Stephan, Immune system, CUSIP, Stealth, Therapy, Security (finance)

Following the reverse stock split, the Company’s common stock will continue to trade on The Nasdaq Capital Market under the symbol “NBSE” with the new CUSIP number, 64132K201.

Key Points: 
  • Following the reverse stock split, the Company’s common stock will continue to trade on The Nasdaq Capital Market under the symbol “NBSE” with the new CUSIP number, 64132K201.
  • The reverse stock split will not change the authorized number of shares of the Company’s common stock.
  • At the Company’s annual meeting of stockholders held on September 8, 2022, the Company’s stockholders approved the reverse stock split in connection with the Company’s common stock and gave the Company’s board of directors discretionary authority to select a ratio for the reverse stock split ranging from 1-for-5 shares to 1-for-20 shares.
  • Standard Registrar and Transfer Company will provide instructions to any stockholders with certificates regarding the process in connection with the exchange of pre-reverse stock split stock certificates for ownership in book-entry form or stock certificates on a post-reverse stock split basis.

NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors™

Retrieved on: 
Monday, May 22, 2023
Dispersity, CRISPR, DNA, Gene, Conference call, Annual general meeting, Gene editing, Enzyme, Mutation, Dietrich Stephan, ET, Development, Genome, Patient, Immune system, Nucleic acid, Frameshift mutation, Cytokine, Research, LNP, Therapy, Safety, Conference, PBS, DNA repair, Vaccine, Stealth

“We are excited to announce preclinical data from our Stealth Editors development program that were presented during the ASGCT 2023 Annual Meeting.

Key Points: 
  • “We are excited to announce preclinical data from our Stealth Editors development program that were presented during the ASGCT 2023 Annual Meeting.
  • Overview of Preclinical Studies and Results Presented at ASGCT 2023 Annual Meeting:
    Ex vivo editing with Stealth Editors - The Company investigated the capabilities of a new editing system to effectively edit human cells ex vivo.
  • The results of this study show PBMCs treated with a Stealth Editor did not impact cell viability.
  • These data demonstrate that NeuBase has overcome the challenge of how to encapsulate Stealth Editors and sets the stage to move this program into in vivo studies.

NeuBase Reports Business Update and Financial Results for the First Quarter of 2023

Retrieved on: 
Thursday, May 11, 2023
KRAS, Abstract, CRISPR, Gene, Quarter, Gene editing, Mutation, Research, Dietrich Stephan, Chemistry, Public expenditure, Immune system, Annual general meeting, Cell, Nucleic acid, Stealth, Therapy, Society, Genome, Pharmaceutical industry, Vaccine, Cryptocurrency

PITTSBURGH, May 11, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today reported its financial results for the three-month period ended March 31, 2023 and other recent developments.

Key Points: 
  • “To date in 2023, we have made steady progress advancing the development of our gene editing application based on our PATrOL™ platform.
  • PNAs have been shown to engage the double-stranded human genome due to their high binding affinity and exquisite sequence selectivity.
  • This is the approach behind our in vivo gene editing platform,” stated Dietrich A. Stephan, Ph.D., Founder and Chief Executive Officer of NeuBase.
  • Financial Results for the Quarter Ended March 31, 2023
    As of March 31, 2023, the Company had cash and cash equivalents of approximately $13.8 million, compared with approximately $17.4 million as of December 31, 2022.

NeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting

Retrieved on: 
Tuesday, May 2, 2023
Abstract, Gene, Gene editing, Toxicology, Myotonic dystrophy, Dietrich Stephan, Pharmacokinetics, Immune system, Cell, Therapy, Society, Biodistribution, Pharmaceutical industry

PITTSBURGH, May 02, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced two abstracts have been accepted for two oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting, which will take place in Los Angeles, CA and virtually on May 16-20, 2023.

Key Points: 
  • PITTSBURGH, May 02, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced two abstracts have been accepted for two oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting, which will take place in Los Angeles, CA and virtually on May 16-20, 2023.
  • Details of the oral presentations are listed below, and the full abstracts are available on the ASGCT meeting website .
  • Toxicology, Pharmacokinetics and Biodistribution of a PATrOL™-Enabled Investigational Genetic Therapy for Myotonic Dystrophy, Type 1